Oncology

By fitting into existing hospital rooms, Mevion's newly CE-Marked proton therapy system aims to slash costs and expand access to advanced cancer treatment.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

New research reveals how stomach cancer cells hijack healthy tissue to build supportive 'nests' in distant organs, opening a new front in the war on metastasis.

Japan becomes the first nation outside Israel to approve Alpha DaRT, a highly precise therapy for untreatable head and neck cancers. Here’s what it means.

The healthcare specialist reported a staggering 2025 net loss due to a write-down, but projects 30% revenue growth fueled by new contracts.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

Caidya appoints veteran Michael Clay as COO, leveraging his deep Asia-Pacific expertise to scale operations and solidify its position in the CRO market.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

As Legacy Community Health embarks on a historic expansion, new COO Aaron Stewart is tasked with steering Texas's largest FQHC to serve more communities.

A former Regeneron exec who built a blockbuster drug joins a medtech startup, signaling a major push to disrupt the multi-billion dollar chemo-port market.

Celebrating 10 years, Maryland's first proton center has treated 6,000 patients by blending advanced technology with a unique model for affordable care.

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.